Clinical Development, Gene Editing, Gene Sequencing and Marketing

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Clinical Development

Gene Editing

Gene Sequencing

Marketing

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

pharmaphorum

APRIL 23, 2021

Vertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Obsidian Therapeutics $75 million upfront to access its technology platform. . Vertex is taking over 60% of the costs of the programme in return for getting the same proportion of profits on sales if CTX001 reaches the market.

Gene Editing

Gene Editing Genetics Drugs Gene

Touchlight boosts DNA manufacturing capacity with latest expansion

Pharmaceutical Technology

MAY 26, 2023

As per the company, dbDNA is suitable for rapid, scalable manufacture of GMP DNA and can incorporate gene sequences of sizes ranging from 500bp to 20kb, which are typically unstable as pDNA. Touchlight estimates that the DNA market is currently worth $1bn and will grow 20% annually until 2030.

DNA

DNA Manufacturing Gene Therapy Gene

Clinical Research Informer

Vertex eyes controllable genetic drugs with $1.3bn Obsidian alliance

Touchlight boosts DNA manufacturing capacity with latest expansion

Stay Connected